Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Subpopulation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    107 result(s) found for: Subpopulation. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2016-001627-31 Sponsor Protocol Number: CanStem303C Start Date*: 2016-12-20
    Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc.
    Full Title: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
    Medical condition: Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic (Stage IV).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BE (Completed) CZ (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024393-19 Sponsor Protocol Number: 20101217 Start Date*: 2012-04-16
    Sponsor Name:Amgen, Inc.
    Full Title: A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals
    Medical condition: Glucocorticoid-induced osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004859 10031287 Osteoporosis steroid-induced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) NL (Completed) CZ (Completed) ES (Completed) PL (Completed) DE (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-016488-12 Sponsor Protocol Number: C13011 Start Date*: 2011-07-12
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn’s Disease
    Medical condition: Moderate to Severe Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) HU (Completed) DE (Completed) AT (Completed) BE (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006556-21 Sponsor Protocol Number: CRAD001J2301 Start Date*: 2009-09-26
    Sponsor Name:Novartis Pharma Service AG
    Full Title: Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Adva...
    Medical condition: HER2+ locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) IT (Completed) IE (Completed) BE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001076-11 Sponsor Protocol Number: CTQJ230A12301 Start Date*: 2019-12-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with establishe...
    Medical condition: Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051614 Arteriosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) SK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) SE (Trial now transitioned) NL (Ongoing) BG (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004902-82 Sponsor Protocol Number: BO28407 Start Date*: 2014-01-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCL...
    Medical condition: HER2-positive operable primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) CZ (Completed) ES (Temporarily Halted) NO (Completed) BE (Prematurely Ended) SE (Prematurely Ended) PL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-008195-13 Sponsor Protocol Number: 2008-008195-13 Start Date*: 2009-02-18
    Sponsor Name:Swedish Institute for Infectious Disease Control (SMI)
    Full Title: An immunogenicity and safety study of combined adsorbed tetanus, low dose diphtheria and acellular pertussis vaccine (Td5ap and Td1aP) given as a school-leaving booster to 14-15-year-old children p...
    Medical condition: Two vaccines against diphtheria, tetanus and pertussis will be tested and immune respons investigated in 14-15-year-old children primed with a five component acellular pertussis vaccine at 3, 5 and...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003437-15 Sponsor Protocol Number: P170922J Start Date*: 2019-04-03
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: Rituximab from the FIRst Episode of Idiopathic Nephrotic Syndrome
    Medical condition: Minimal Change Nephrotic Syndrome (MCNS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10029168 Nephrotic syndrome with lesion of minimal change glomerulonephritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020684-20 Sponsor Protocol Number: CLAF237A23135 Start Date*: 2010-09-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or witho...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) GB (Completed) BE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-007689-52 Sponsor Protocol Number: 0653A-133 Start Date*: 2009-05-27
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg...
    Medical condition: Lipids not at goal in diabetic patients with cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) DE (Completed) LV (Completed) AT (Completed) EE (Completed) IT (Completed) PT (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000802-46 Sponsor Protocol Number: D169CC00001 Start Date*: 2018-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur...
    Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-003205-15 Sponsor Protocol Number: GO29527 Start Date*: 2015-11-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHE...
    Medical condition: NON−SMALL CELL LUNG CANCER
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) NL (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006075-75 Sponsor Protocol Number: AK106 II-01 Start Date*: 2009-04-22
    Sponsor Name:Asahi Kasei Pharma Corporation
    Full Title: A Phase IIa, Multi-Centre, Randomized, Double-Blind, Two-Part, Controlled, Repeated-Dose Study of AK106-001616 in Patients with Rheumatoid Arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-004596-31 Sponsor Protocol Number: NL62772 Start Date*: 2019-03-25
    Sponsor Name:UMC Utrecht
    Full Title: CeRebrUm and CardIac protection with Allopurinol in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass
    Medical condition: Brain injury in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010495 Congenital heart disease NOS LLT
    20.0 10029205 - Nervous system disorders 10067967 Brain injury PT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002782-20 Sponsor Protocol Number: H3E-MC-JMHH Start Date*: 2005-04-15
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal Cancer
    Medical condition: platinum sensitive recurrent ovarian or primary peritoneal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021622-35 Sponsor Protocol Number: C2T Start Date*: 2011-08-11
    Sponsor Name:Dean of Medical Faculty of Goethe University Frankfurt
    Full Title: A monocenter, non-controlled, non-randomized IST to compare bioavailability of Kaletra softgelcapsules or -suspension to Kaletra tablets in pediatric patients – C2T
    Medical condition: Pediatric patients with diagnosed HIV1- infection aged 3 to 18 years
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004429-26 Sponsor Protocol Number: CMP0119 Start Date*: 2020-05-08
    Sponsor Name:PRZEDSIEBIORSTWO FARMACEUTYCZNE LEK-AM SPÓŁKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
    Full Title: A multicentre, randomized, open-label, cross-over equivalence study to compare the pharmacodynamic properties, safety, and tolerability of a new combination dry powder of fluticasone propionate and...
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002571-34 Sponsor Protocol Number: CBKM120F2303 Start Date*: 2012-08-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metas...
    Medical condition: This study will evaluate whether the addition of daily BKM120 to fulvestrant is effective and safe in treating patients with hormone receptor-positive HER2 negative locally advanced or metastatic b...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) NO (Prematurely Ended) IT (Prematurely Ended) SE (Temporarily Halted) NL (Prematurely Ended) GR (Temporarily Halted) FI (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) BE (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000849-38 Sponsor Protocol Number: CRAD001C2223 Start Date*: 2005-08-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara®) to investigate the value of adding RAD001 to letrozole as a first-line t...
    Medical condition: The treatment of advanced breast cancer aims at reducing tumor size, slowing progression and metastasis and reducing complications such as fatigue, bone fracture and hypercalcemia. Women with tumor...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001107-33 Sponsor Protocol Number: NL76863.068.21 Start Date*: 2021-03-10
    Sponsor Name:MUMC
    Full Title: SARS-CoV-2 vaccination response in patients with haematological disease
    Medical condition: multiple myeloma chronic lymphocytic leukemia, non-Hodgkin lymphoma,
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 14:22:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA